- The U.S. Department of Health and Human Services announced that it, in partnership with the Department of Defense, agreed to purchase another 105 million doses of Pfizer’s COVID-19 shot — for $3.2 billion
- The contract is intended to supply shots for a coming fall injection campaign and includes options to purchase up to 300 million doses
- The decision came after a June 28 meeting of the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), which recommended that an Omicron-specific component be included in COVID-19 booster shots in the U.S.
- Pfizer stands to profit significantly from the contract and has forecast that its COVID-19 shot sales will reach $32 billion in 2022
- VRBPAC voted 19-2 in favor of recommending booster shots that are Omicron-specific, even though panel members expressed uncertainty and guesswork surrounding the booster rollout’https://www.theepochtimes.com/us-gives-pfizer-3-2-billion-for-ineffective-covid-vax_4592843.html?est=UigdwmwEKXx2q7GcV2%2FNCvzt0oyG8Bmi9bCPh2Chl7kfcEprKav6%2FKyOGaupfjV0cg%3D%3D